WIZP - Wize Pharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2400
-0.0090 (-3.61%)
As of 12:49PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.2490
Open0.1650
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1650 - 0.2490
52 Week Range0.1000 - 2.3400
Volume6,449
Avg. Volume7,140
Market Cap2.611M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Wize Pharma Enters Exclusive License Agreement for Ophthalmic Non-viral Gene Therapy Technology
    PR Newswire

    Wize Pharma Enters Exclusive License Agreement for Ophthalmic Non-viral Gene Therapy Technology

    HOD HASHARON, Israel, Sept. 9, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has entered into an Exclusive License Agreement with U.S.-based Copernicus Therapeutics, Inc., pursuant to which, at the closing, it will be granted exclusive rights to license, develop and commercialize products based on a non-viral gene therapy technology developed by Copernicus for the treatment of Choroideremia (CHM). "We are very pleased and excited to enter into this agreement with Copernicus.

  • Zacks Small Cap Research

    WIZP: Wize Pharma - results on track in 2Q19

    Wize Pharma, Inc. (WIZP) is a clinical-stage company focused on developing an in-licensed product, for the treatment of dry eye syndrome (DES) and related conditions including Sjögren’s syndrome and conjunctivochalasis (CCH). LO2A is approved and marketed by its inventor in several European nations, with over 1.5 million packages sold in 2018. Wize has the rights to develop LO2A for the US, China, Israel and the option to license the rights for additional markets, including those where LO2A is currently sold.

  • Wize Pharma Retains Life Science Advisory Firm Lighthouse BioPartners to Support Potential Pharma Partnership Deals for its Lead Asset LO2A
    PR Newswire

    Wize Pharma Retains Life Science Advisory Firm Lighthouse BioPartners to Support Potential Pharma Partnership Deals for its Lead Asset LO2A

    Having recently completed a successful Phase II study of LO2A in the symptomatic treatment of DES in patients with moderate to severe conjunctivochalasis (CCh), we look ahead to announcing top line results in our Phase IV study of LO2A for symptomatic improvement of DES in patients with Sjögren's Syndrome in the first quarter of 2020.

  • Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments
    PR Newswire

    Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

    HOD HASHARON, Israel, June 28, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (CNBX) have together created and adopted a business plan for their joint venture (JV), a new entity focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the JV was a condition for the planned venture to move forward. Having assessed the regulatory pathway for eyedrops containing cannabinoids or cannabinoid strings, we are eagerly engaging in technology development and clinical advancement.

  • Wize Pharma Interview to Air on Bloomberg International on the RedChip Money Report June 16, 2019
    PR Newswire

    Wize Pharma Interview to Air on Bloomberg International on the RedChip Money Report June 16, 2019

    LOS ANGELES, June 14, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced an interview with its CEO, Noam Danenberg, will air on The RedChip Money Report television program. The interview will air Sunday, June 16, on Bloomberg International, available in 149 million homes across Europe, the Middle East, and Africa. In the exclusive interview, Danenberg discusses Wize Pharma's recent developments, including the Company's successfully completed Phase II study of LO2A for the symptomatic treatment of dry eye syndrome in patients with moderate to severe conjunctivochalasis, status of the Company's ongoing Phase IV study in Sjogren's, other clinical and corporate developments, as well as recent M&A transactions in the dry eye treatment space that validate the growing value of Wize's assets for ophthalmic indications.

  • ACCESSWIRE

    Wize Pharma to Present at the 9th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5 at 12:00 PM PST / 3:00 PM EST. Chief Executive Officer Noam Danenberg will be presenting and meeting with investors. "We look forward to updating investors on the latest advancements at Wize Pharma including our positive Phase II clinical results and the opportunities we are developing in the $3.7 billion global market for the treatment of ophthalmic disorders," Noam Danenberg stated.

  • Wize Pharma Issues Letter to Shareholders
    PR Newswire

    Wize Pharma Issues Letter to Shareholders

    HOD HASHARON, Israel, May 21, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today issued a Letter to Shareholder. Concurrently, I increased my stake in the company through a $400,000 investment at a price of about $1.00 per share.

  • Zacks Small Cap Research

    WIZP: Performing according to plan

    By Beth Senko, CFA OTC:WIZP READ THE FULL WIZP RESEARCH REPORT On May 15, Wize Pharma Inc. (OTC:WIZP) posted first quarter results in line with expectations. Net income improved to $0.15 million from a ...

  • Zacks Small Cap Research

    WIZP: Initiating coverage – a better treatment for dry eye

    Wize Pharma, Inc. (WIZP) is seeking FDA approval for LO2A, a proprietary formulation of artificial tears for the treatment of Sjögren’s and conjunctivochalasis (CCH) in dry eye syndrome. While the competitive landscape is significant, we believe the company will carve out a modest share of the US market based on LO2A’s approval for DES, Sjögren’s and CCH in four European nations if it receives FDA approval.

  • Wize Pharma to Present at ThinkEquity Conference on May 2, 2019 in New York City
    PR Newswire

    Wize Pharma to Present at ThinkEquity Conference on May 2, 2019 in New York City

    HOD HASHARON, Israel, April 30, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it will present at the ThinkEquity Conference on May 2, 2019 at 2:30 pm ET at the Lotus Room of the Mandarin Oriental Hotel in New York City. The ThinkEquity conference brings together companies in healthcare, technology, finance, and energy with institutional and accredited investors. ThinkEquity is a division of Fordham Financial Management, Inc.

  • Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis
    PR Newswire

    Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis

    - LO2A eye drops met primary efficacy endpoint for DES in patients with moderate to severe CCh - LO2A safety confirmed in all measured parameters - $3.7 billion global DES treatment market expected to ...

  • Wize Pharma's CEO Noam Danenberg Increases Stake in Company
    PR Newswire

    Wize Pharma's CEO Noam Danenberg Increases Stake in Company

    HOD HASHARON, Israel, April 24, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today the Company's Chief Executive Officer, Mr. Noam Danenberg, has increased his ownership of common stock in Wize Pharma to 1.66% of the Company's outstanding shares, and increased his beneficial ownership including common stock and other convertible securities to 7.70%.

  • Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer
    PR Newswire

    Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer

    HOD HASHARON, Israel, April 23, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, is pleased to announce that Mr. Mark Sieczkarek has been appointed Chairman of Wize Pharma's Board of Directors, replacing Mr. Noam Danenberg, who will become the Company's Chief Executive Officer, effective April 23, 2019.

  • LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary
    PR Newswire

    LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary

    Wize Pharma Pursuing LO2A In Same and Related Indications in Additional Geographies LO2A Receives Third Therapeutic Indication in EU Country HOD HASHARON, Israel, March 11, 2019 /PRNewswire/ --  Wize Pharma, ...

  • Cannabics Pharmaceuticals Closes Agreement With Wize Pharma
    PR Newswire

    Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

    BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.

  • Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics
    PR Newswire

    Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

    Companies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions HOD HASHARON, Israel , March 6 , 2019  /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" ...

  • Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
    PR Newswire

    Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics

    BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Initially announced in a press release on June 29, 2018, the two companies have been advancing planning and have concluded, that subject to completing a mutually agreeable business plan and obtaining an expert opinion in order to identify a potential FDA route for ophthalmic therapy containing cannabinoids, each expected to occur within 30 days, that they are ready to form a joint venture (JV) company, for the purpose of researching, developing, and administering cannabinoid formulations to treat ophthalmic disorder indications.

  • Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions
    PR Newswire

    Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions

    HOD HASHARON, Israel, Feb. 7, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreement to form a joint venture (JV) company for the purpose of researching, developing and administering cannabinoid formulations to treat ophthalmic conditions  with Cannabics Pharmaceuticals Inc. ("Cannabics") (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects. The agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids.  Upon effectiveness, Wize shall issue 900,000 shares of its common stock to Cannabics and Cannabics shall issue 2,263,944 shares of its common stock to Wize.  The agreement shall expire if the parties have not approved a business plan by June 30, 2019.

  • Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye
    PR Newswire

    Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye

    Data shows statistically significant improvement after 3 months of treatment in both objective and subjective measures HOD HASHARON, Israel, Jan. 10, 2019 /PRNewswire/ -- Wize Pharma, Inc.  ("Wize ...

  • Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis
    PR Newswire

    Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis

    HOD HASHARON, Israel, Nov. 20, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh).